Clinical trials: Sjögren's Syndrome
Dry Eye
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
The study was planned to be conducted in 2 parts: Part 1 to determine the efficacy and safety of ECF843 vs vehicle, followed by Part 2 with additional exploratory assessments of ECF843 vs Vehicle.
- Trial name
- NCT04391894
- Testing
- ECF843, ECF843 vehicle
- Where
- 52 sites in United States
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Autoimmune Disorder, Rheumatoid Arthritis
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib…
- Conditions
- Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
- Trial name
- NCT04186871
- Testing
- branebrutinib, abatacept
- Where
- 81 sites in United States, Argentina and 8 more
- Volunteers
- 119 people
- Sponsor
- Bristol-Myers Squibb
Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a study to evaluate the efficacy and safety of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
- Trial name
- NCT02334306
- Testing
- AMG 557/MEDI5872
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 32 people
- Sponsor
- MedImmune LLC
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren Syndrome
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.
- Trial name
- GLIDER (NCT04700280)
- Testing
- GLPG3970
- Where
- 10 sites in Germany, Greece and 3 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Sjogren's Syndrome
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525).
- Trial name
- TWINSS Extn (NCT04541589)
- Testing
- Iscalimab
- Where
- 62 sites in United States, Argentina and 21 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Primary Sjögren's Syndrome
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
- Trial name
- NCT02291029
- Testing
- CFZ533 active - Cohort 1, CFZ533 active - Cohort 2, CFZ533 active -Cohort 3
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Sjögren's Syndrome, Sjogren's Syndrome
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against…
- Trial name
- phaethuSA (NCT04572841)
- Testing
- SAR441344
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Primary Sjögren's Syndrome
A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.
- Trial name
- rho (NCT05817669)
- Testing
- Efgartigimod
- Where
- 17 sites in Belgium, Hungary and 2 more
- Volunteers
- 34 people
- Sponsor
- argenx
Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
- Trial name
- SS (NCT04129164)
- Testing
- VIB4920
- Where
- 62 sites in United States, Argentina and 10 more
- Volunteers
- 183 people
- Sponsor
- Amgen
Primary Sjögren's Syndrome
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.
- Trial name
- NCT02775916
- Testing
- CDZ173
- Where
- 2 sites in Germany, Hungary
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren's Syndrome
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
The purpose of the study is to find out if the experimental study agent, baminercept, is effective in treating patients with Sjögren's syndrome.
- Trial name
- NCT01552681
- Testing
- Baminercept
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Primary Sjögren's Syndrome
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS).
- Trial name
- Rho plus (NCT06203457)
- Testing
- Efgartigimod
- Where
- 11 sites in Belgium, Hungary and 1 more
- Volunteers
- 24 people
- Sponsor
- argenx
Sjögren's Syndrome, Xerostomia
Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects
Background: Sjögren's syndrome is an autoimmune disease (where the immune system attacks normal body tissues) that affects the salivary glands.
- Trial name
- NCT01316770
- Testing
- Dexamethasone Parotid Irrigation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Fibromyalgia, Multiple Sclerosis
e-Mobile Tablet for People With Chronic Conditions
Maintaining a healthy diet and engaging in routine physical activity may help decrease severity of symptoms, prevent secondary conditions, and slow functional decline in people with disabling neuromusculoskeletal conditions.
- Conditions
- Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome
- Trial name
- NCT02833311
- Testing
- Computer Tablet Group, Paper and Pencil Group, Contact Control Group
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Case Western Reserve University
Primary Sjögren's Syndrome
PD of VAY736 in Patients With Primary Sjögren's Syndrome
This study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients
- Trial name
- CVAY736X2201 (NCT02149420)
- Testing
- VAY736
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren's Syndrome
A Study of INCB050465 in Primary Sjögren's Syndrome
The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren's syndrome (SS).
- Trial name
- NCT03627065
- Testing
- Parsaclisib
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation